Purpose. The diagnosis, staging, and management of renal cell carcinoma (RCC) are reviewed. The mechanism, pharmacokinetics, toxicity, clinical activity, and application of molecularly targeted ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

Telix CEO Chris Behrenbruch has been awarded a 68% base pay rise ahead of expected FDA approval of its kidney ... Read More ...

Two patients (1.6%) had recurrence of renal cell cancer at 16 and 35 months post ... this patient was disease-free on imaging performed prior to expiration. Kaplan-Meier curves were generated ...

Medically reviewed by Gagandeep Brar, MD Hypernephroma (also called renal cell adenocarcinoma or clear-cell carcinoma of the ...

Diagnosis. Stage IV, T3bN0M1 clear cell renal cell carcinoma, with an associated tumor thrombus extending into the vena cava. Management. The patient was treated with neoadjuvant sunitinib ...

Telix submits BLA to US FDA for TLX250-CDx kidney cancer imaging: Melbourne, Australia Tuesday, December 31, 2024, 15:00 Hrs [IST] Telix, a biopharmaceutical company focused on th ...

We evaluated ctDNA status and dynamics during surveillance and as part of TRM with clinical outcomes in both patients with clear cell renal cell carcinoma (ccRCC) and non–clear cell renal cell ...

Telix Pharmaceuticals Limited (TLX) said that it has submitted its Biologics License Application (BLA) to the U.S. Food and Drug ...

kidney cancer imaging 2. TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and ...

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics ...